Ceftobiprole medocaril: BAL5788, JNJ 30982081, JNJ30982081, RO 65-5788, RO 655788

Drugs in R and D

Volumn 7, Issue 5, 2006, Pages 305-311

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; CEFTOBIPROLE MEDOCARIL; CEFTRIAXONE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; DIABETIC FOOT; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG SAFETY; DRUG SOLUBILITY; DRUG TOLERABILITY; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SKIN INFECTION; SKIN STRUCTURE; TASTE DISORDER; VOMITING;

ANIMALS; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; CLINICAL TRIALS, PHASE III; CLINICAL TRIALS, PHASE III AS TOPIC; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 33747873937     PISSN: 11745886     EISSN: 11745886     Source Type: Journal    
DOI: 10.2165/00126839-200607050-00003     Document Type: Review

References (28)

1. Basilea Pharmaceutica AG. Basilea Enters a Global Collaboration with Johnson & Johnson's Affiliate Cilag AG International for Basilea's Phase III, First-in-Class Antibiotic Ceftobiprole (BAL5788). Media Release: 3 Feb 2005. Available from URL: http://www.basilea.com
2. Ribozyme Pharmaceuticals Inc. RPI Reports Third Quarter Financial Results. Media Release: 14 Nov 2002. Available from URL: http://www.rpi.com
3. Basilea Pharmaceutica Ltd. FDA Fast Track Designation for Basilea's Novel Broad Spectrum Antibiotic. Media Release: 10 Mar 2003. Available from URL: http://www.basileapharma.com
4. Basilea Pharmaceutica AG. Additional FDA Fast Track Designation for Basilea's Novel First-In-Class Antibiotic. Media Release: 16 Jun 2004. Available from URL: http://www.basileapharma.com
5. Basilea Pharmaceutica Ltd. Basilea Pharmaceutica Ltd. (SWX: BSLN) reports its interim results. Media Release: 24 Aug 2005. Available from URL: http://www.basilea.com
6. Basilea Pharmaceutica Ltd. Basilea's first-in-class antibiotic ceftobiprole aims at broader indication including diabetic foot infections. Media Release: 11 Oct 2005. Available from URL: http://www.basileapharma.com
7. Theil F-P, Schonlein K, Schenk P, et al. Pharmacokinetics of the cephalosporin RO 63-9141 in five animal species - extrapolation to man. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy: 239 (Poster), 24 Sep 1998
8. Hebeisen P, Gross G, Heinke-Krauss I. Synthesis, physicochemical and pharmacokinetic properties of water soluble prodrugs of Ro 63-9141/000. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy: 239, 24 Sep 1998
9. Schmitt-Hoffmann AH, Roos B, Spickermann J, et al. Influence of dose and infusion duration on the time above MIC of ceftobiprole in healthy volunteers. Clinical Microbiology and Infection 11 (Suppl. 2): 273, Apr 2005
10. Schmitt-Hoffmann AH, Harsch M, Heep M, et al. BAL5788 in patients with complicated skin and skin structure infections caused by Gram-positive pathogens including methicillin-resistant Staphylococcus species. Interim pharmacokinetic results from 20 patients. 14th European Congress of Clinical Microbiology and Infectious Diseases 10 (Suppl. 3): 277 (plus poster) abstr. P1031, 1 May 2004
11. Roos B, Schmitt-Hoffmann A, Schleimer M, et al. Safety and pharmacokinetics of BAL5788 in healthy subjects with normal or impaired renal function. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy: 5 (plus poster) abstr. A-23, 14 Sep 2003
12. Schmitt-Hoffmann AH, Roos B, Heep M, et al. Influence of gender on the pharmacokinetics of BAL9141 after intravenous infusion of Pro-drug BAL5788. Clinical Microbiology and Infection 10 (Suppl. 3): 276-277 (plus poster), May 2004
13. Basilea Pharmaceutica Ltd. Basilea (SWX: BSLN) announces positive phase III results for ceftobiprole, its first-in-class anti-MRSA cephalosporin. Media Release: 2 Mar 2006. Available from URL: http://www.basilea.com
14. Basilea Pharmaceutica AG. Positive Phase II Results for Basilea's Novel First-In-Class Antibiotic. Media Release: 3 Mar 2004. Available from URL: http://www.basileapharma.com
15. Schmitt-Hoffmann A, Roos B, Schleimer M, et al. Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrobial Agents and Chemotherapy 48: 2570-2575, No. 7, Jul 2004
16. Schmitt-Hoffmann A, Nyman L, Roos B, et al. Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrobial Agents and Chemotherapy 48: 2576-2580, No. 7, Jul 2004
17. Hohl P, Angehrn P, Then RL, et al. Ro 63-9141, a novel board-spectrum anti-MRSA pyrrolidinone cephalosporin: Part I: activity against aerobic Gram-negatives. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy: 238-239 (Poster), 24 Sep 1998
18. Hohl P, Angehrn P, Then RL, et al. Ro 63-9141, a novel broad-spectrum anti-MRSA pyrrolidinone cephalosporin. Part II: activity against Gram-positives including MRSA. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy: 239 (Poster), 24 Sep 1998
19. Entenza JM, Hohl P, Heinze-Krauss I, et al. BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrobial Agents and Chemotherapy 46: 171-177, Jan 2002
20. Azoulay-Dupuis E, Bédos JP, Mohler J, et al. Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia. Antimicrobial Agents and Chemotherapy 48: 1105-1111, No. 4, Apr 2004
21. Schmitt-Hoffmann A, Yin L, Calhoun J, et al. Distribution of ceftobiprole in bone matrix and bone marrow in a rabbit MRSA osteomyelitis model. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy: 53 (plus poster) abstr. B-2007, Dec 2005
22. Basilea Pharmaceutica Ltd. Basilea's ceftobiprole highlight of ICAAC session. Media Release: 20 Dec 2005. Available from URL: http://www.basilea.com
23. Zbinden R, Puenter V, Von Graevenitz A. Ro 63-9141 (Ro 63), a novel broad-spectrum anti-MRSA pyrrolidinone cephalosporin: activity against Gram-negative nonfermenters. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy: 237 (Poster), 24 Sep 1998
24. Page M, Bur D, Hebeisen P. Inhibition of the penicillin-binding proteins of methicillin-resistant Staphylococcus aureus by pyrrolidinone-3-ylidenemethyl cephems. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy: 238 (plus poster), 24 Sep 1998
25. Deshpande IM. Antimicrobial potency and spectrum for Ro63-9141, a novel cephalosporin with activity against methicillin-resistant staphylococci (MRS). 41st Interscience Conference on Antimicrobial Agents and Chemotherapy: 211 (plus poster) abstr. 375, 22 Sep 2001
26. Issa NC, Rouse MS, Piper KE, et al. In vitro activity of BAL9141 against clinical isolates of Gram-negative bacteria. Diagnostic Microbiology and Infectious Disease 48: 73-75, No. 1, Jan 2004
27. Bogdanovich T, Ednie LM, Shapiro S, et al. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrobial Agents and Chemotherapy 49: 4210-4219, No. 10, Oct 2005
28. Heep M, Querner S, Harsch M, et al. BAL5788, the first of a new class of anti-MRSA cephalosporins: microbiological results from a phase II study in complicated skin and skin structure infections. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy: 380-381 (plus poster) abstr. L-361, 30 Oct 2004